In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation (2022)

Abstract

Atrial fibrillation is one of the most common arrhythmias that affects over 2.2 million Americans each year. Catheter ablation, one of the effective treatments, has shown high rate of success in treating paroxysmal atrial fibrillation. Currently, radiofrequency which is being used for catheter ablation is an invasive procedure. Measurable morbidity and significant costs and time are associated with this modality of treatment of permanent or persistent atrial fibrillation. In order to address these issues, a transesophageal ultrasound applicator for noninvasive cardiac ablation was designed, developed and evaluated. The ultrasound energy delivered by the phased array was used to create a lesion in the myocardial tissue. Various factors, simulation results of transducer arrays, current transesophageal medical devices, and throat anatomy, were considered while designing a phased ultrasound transducer that can be inserted into the esophagus. For this research, a two-dimensional sparse phased array with flat tapered elements was fabricated and evaluated in in vivo experiments. Five pigs were anesthetized; the array was passed transesophagealy and positioned over the heart. An operating frequency of 1.6 MHz and 8∼15 minutes of array operation resulted in both single and multiple lesions on atrial and ventricular myocardium. The average size of lesions was 5.1±2.1mm in diameter and 7.8±2.5mm in length. Experimental results indicate that the array delivered sufficient power to produce ablation at the focal point while not grossly damaging the tissue surrounding the area of interest. These results demonstrate a potential application of the ultrasound applicator for noninvasive transesophageal cardiac surgery in atrial fibrillation treatment.

Original languageEnglish (US)
Title of host publication9th International Symposium on Therapeutic Ultrasound - ISTU 2009
Pages333-336
Number of pages4
DOIs
StatePublished - 2010
Event9th International Symposium on Therapeutic Ultrasound, ISTU 2009 - Aix-en-Provence, France
Duration: Sep 24 2009Sep 26 2009

Publication series

NameAIP Conference Proceedings
Volume1215
ISSN (Print)0094-243X
ISSN (Electronic)1551-7616

Other

Other9th International Symposium on Therapeutic Ultrasound, ISTU 2009
Country/TerritoryFrance
CityAix-en-Provence
Period9/24/099/26/09

All Science Journal Classification (ASJC) codes

  • Physics and Astronomy(all)

Fingerprint

Dive into the research topics of 'In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation'. Together they form a unique fingerprint.

View full fingerprint

Cite this

  • APA
  • Author
  • BIBTEX
  • Harvard
  • Standard
  • RIS
  • Vancouver

Jaiswal, D., Werner, J., Park, E. J., Francischelli, D., & Smith, N. B. (2010). In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation. In 9th International Symposium on Therapeutic Ultrasound - ISTU 2009 (pp. 333-336). (AIP Conference Proceedings; Vol. 1215). https://doi.org/10.1063/1.3367174

Jaiswal, Devina ; Werner, Jacob ; Park, Eun Joo et al. / In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation. 9th International Symposium on Therapeutic Ultrasound - ISTU 2009. 2010. pp. 333-336 (AIP Conference Proceedings).

@inproceedings{206f3822d4fd4b259a1b4f12133f15f0,

title = "In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation",

abstract = "Atrial fibrillation is one of the most common arrhythmias that affects over 2.2 million Americans each year. Catheter ablation, one of the effective treatments, has shown high rate of success in treating paroxysmal atrial fibrillation. Currently, radiofrequency which is being used for catheter ablation is an invasive procedure. Measurable morbidity and significant costs and time are associated with this modality of treatment of permanent or persistent atrial fibrillation. In order to address these issues, a transesophageal ultrasound applicator for noninvasive cardiac ablation was designed, developed and evaluated. The ultrasound energy delivered by the phased array was used to create a lesion in the myocardial tissue. Various factors, simulation results of transducer arrays, current transesophageal medical devices, and throat anatomy, were considered while designing a phased ultrasound transducer that can be inserted into the esophagus. For this research, a two-dimensional sparse phased array with flat tapered elements was fabricated and evaluated in in vivo experiments. Five pigs were anesthetized; the array was passed transesophagealy and positioned over the heart. An operating frequency of 1.6 MHz and 8∼15 minutes of array operation resulted in both single and multiple lesions on atrial and ventricular myocardium. The average size of lesions was 5.1±2.1mm in diameter and 7.8±2.5mm in length. Experimental results indicate that the array delivered sufficient power to produce ablation at the focal point while not grossly damaging the tissue surrounding the area of interest. These results demonstrate a potential application of the ultrasound applicator for noninvasive transesophageal cardiac surgery in atrial fibrillation treatment.",

author = "Devina Jaiswal and Jacob Werner and Park, {Eun Joo} and David Francischelli and Smith, {Nadine Barrie}",

year = "2010",

doi = "10.1063/1.3367174",

language = "English (US)",

isbn = "9780735407589",

series = "AIP Conference Proceedings",

pages = "333--336",

booktitle = "9th International Symposium on Therapeutic Ultrasound - ISTU 2009",

note = "9th International Symposium on Therapeutic Ultrasound, ISTU 2009 ; Conference date: 24-09-2009 Through 26-09-2009",

}

Jaiswal, D, Werner, J, Park, EJ, Francischelli, D & Smith, NB 2010, In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation. in 9th International Symposium on Therapeutic Ultrasound - ISTU 2009. AIP Conference Proceedings, vol. 1215, pp. 333-336, 9th International Symposium on Therapeutic Ultrasound, ISTU 2009, Aix-en-Provence, France, 9/24/09. https://doi.org/10.1063/1.3367174

In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation. / Jaiswal, Devina; Werner, Jacob; Park, Eun Joo et al.

9th International Symposium on Therapeutic Ultrasound - ISTU 2009. 2010. p. 333-336 (AIP Conference Proceedings; Vol. 1215).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation

AU - Jaiswal, Devina

AU - Werner, Jacob

AU - Park, Eun Joo

AU - Francischelli, David

AU - Smith, Nadine Barrie

PY - 2010

Y1 - 2010

N2 - Atrial fibrillation is one of the most common arrhythmias that affects over 2.2 million Americans each year. Catheter ablation, one of the effective treatments, has shown high rate of success in treating paroxysmal atrial fibrillation. Currently, radiofrequency which is being used for catheter ablation is an invasive procedure. Measurable morbidity and significant costs and time are associated with this modality of treatment of permanent or persistent atrial fibrillation. In order to address these issues, a transesophageal ultrasound applicator for noninvasive cardiac ablation was designed, developed and evaluated. The ultrasound energy delivered by the phased array was used to create a lesion in the myocardial tissue. Various factors, simulation results of transducer arrays, current transesophageal medical devices, and throat anatomy, were considered while designing a phased ultrasound transducer that can be inserted into the esophagus. For this research, a two-dimensional sparse phased array with flat tapered elements was fabricated and evaluated in in vivo experiments. Five pigs were anesthetized; the array was passed transesophagealy and positioned over the heart. An operating frequency of 1.6 MHz and 8∼15 minutes of array operation resulted in both single and multiple lesions on atrial and ventricular myocardium. The average size of lesions was 5.1±2.1mm in diameter and 7.8±2.5mm in length. Experimental results indicate that the array delivered sufficient power to produce ablation at the focal point while not grossly damaging the tissue surrounding the area of interest. These results demonstrate a potential application of the ultrasound applicator for noninvasive transesophageal cardiac surgery in atrial fibrillation treatment.

AB - Atrial fibrillation is one of the most common arrhythmias that affects over 2.2 million Americans each year. Catheter ablation, one of the effective treatments, has shown high rate of success in treating paroxysmal atrial fibrillation. Currently, radiofrequency which is being used for catheter ablation is an invasive procedure. Measurable morbidity and significant costs and time are associated with this modality of treatment of permanent or persistent atrial fibrillation. In order to address these issues, a transesophageal ultrasound applicator for noninvasive cardiac ablation was designed, developed and evaluated. The ultrasound energy delivered by the phased array was used to create a lesion in the myocardial tissue. Various factors, simulation results of transducer arrays, current transesophageal medical devices, and throat anatomy, were considered while designing a phased ultrasound transducer that can be inserted into the esophagus. For this research, a two-dimensional sparse phased array with flat tapered elements was fabricated and evaluated in in vivo experiments. Five pigs were anesthetized; the array was passed transesophagealy and positioned over the heart. An operating frequency of 1.6 MHz and 8∼15 minutes of array operation resulted in both single and multiple lesions on atrial and ventricular myocardium. The average size of lesions was 5.1±2.1mm in diameter and 7.8±2.5mm in length. Experimental results indicate that the array delivered sufficient power to produce ablation at the focal point while not grossly damaging the tissue surrounding the area of interest. These results demonstrate a potential application of the ultrasound applicator for noninvasive transesophageal cardiac surgery in atrial fibrillation treatment.

UR - http://www.scopus.com/inward/record.url?scp=77949911643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949911643&partnerID=8YFLogxK

U2 - 10.1063/1.3367174

DO - 10.1063/1.3367174

M3 - Conference contribution

AN - SCOPUS:77949911643

SN - 9780735407589

T3 - AIP Conference Proceedings

SP - 333

EP - 336

BT - 9th International Symposium on Therapeutic Ultrasound - ISTU 2009

T2 - 9th International Symposium on Therapeutic Ultrasound, ISTU 2009

Y2 - 24 September 2009 through 26 September 2009

ER -

Jaiswal D, Werner J, Park EJ, Francischelli D, Smith NB. In vivo evaluations of a phased ultrasound array for transesophageal cardiac ablation. In 9th International Symposium on Therapeutic Ultrasound - ISTU 2009. 2010. p. 333-336. (AIP Conference Proceedings). doi: 10.1063/1.3367174

Top Articles

You might also like

Latest Posts

Article information

Author: Lidia Grady

Last Updated: 10/04/2022

Views: 5784

Rating: 4.4 / 5 (45 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Lidia Grady

Birthday: 1992-01-22

Address: Suite 493 356 Dale Fall, New Wanda, RI 52485

Phone: +29914464387516

Job: Customer Engineer

Hobby: Cryptography, Writing, Dowsing, Stand-up comedy, Calligraphy, Web surfing, Ghost hunting

Introduction: My name is Lidia Grady, I am a thankful, fine, glamorous, lucky, lively, pleasant, shiny person who loves writing and wants to share my knowledge and understanding with you.